CRBP Corbus Pharmaceuticals Holdings Inc

Price (delayed)

$1.99

Market cap

$248.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.14

Enterprise value

$207.65M

Highlights
The company's equity has surged by 102% QoQ
The quick ratio has soared by 96% QoQ
Corbus Pharmaceuticals Holdings's net income has decreased by 30% YoY but it has increased by 12% from the previous quarter
CRBP's debt has soared by 193% year-on-year
Corbus Pharmaceuticals Holdings's revenue has plunged by 92% YoY and by 28% from the previous quarter

Key stats

What are the main financial stats of CRBP
Market
Shares outstanding
125.03M
Market cap
$248.82M
Enterprise value
$207.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.72
Price to sales (P/S)
82.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
73.56
Earnings
Revenue
$2.82M
EBIT
-$95.9M
EBITDA
-$94.24M
Free cash flow
-$93.91M
Per share
EPS
-$1.14
Free cash flow per share
-$0.81
Book value per share
$0.73
Revenue per share
$0.02
TBVPS
$1.2
Balance sheet
Total assets
$140.15M
Total liabilities
$48.63M
Debt
$26.47M
Equity
$91.52M
Working capital
$106.68M
Liquidity
Debt to equity
0.29
Current ratio
5.52
Quick ratio
5.3
Net debt/EBITDA
0.44
Margins
EBITDA margin
-3,338.2%
Gross margin
100%
Net margin
-3,460.1%
Operating margin
-3,837.7%
Efficiency
Return on assets
-89.5%
Return on equity
-182.2%
Return on invested capital
-451.1%
Return on capital employed
-82.3%
Return on sales
-3,397%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRBP stock price

How has the Corbus Pharmaceuticals Holdings stock price performed over time
Intraday
-3.86%
1 week
-8.72%
1 month
22.09%
1 year
-75.03%
YTD
59.2%
QTD
1.02%

Financial performance

How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time
Revenue
$2.82M
Gross profit
$2.82M
Operating income
-$108.34M
Net income
-$97.68M
Gross margin
100%
Net margin
-3,460.1%
Corbus Pharmaceuticals Holdings's revenue has plunged by 92% YoY and by 28% from the previous quarter
CRBP's gross profit has dropped by 92% year-on-year and by 28% since the previous quarter
The operating income is down by 35% year-on-year but it is up by 12% since the previous quarter
Corbus Pharmaceuticals Holdings's net income has decreased by 30% YoY but it has increased by 12% from the previous quarter

Growth

What is Corbus Pharmaceuticals Holdings's growth rate over time

Valuation

What is Corbus Pharmaceuticals Holdings stock price valuation
P/E
N/A
P/B
2.72
P/S
82.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
73.56
Corbus Pharmaceuticals Holdings's EPS has increased by 20% QoQ
The company's equity has surged by 102% QoQ
CRBP's P/B is 80% below its 5-year quarterly average of 13.3 and 52% below its last 4 quarters average of 5.7
Corbus Pharmaceuticals Holdings's revenue has plunged by 92% YoY and by 28% from the previous quarter
The stock's P/S is 51% more than its last 4 quarters average of 54.3 but 8% less than its 5-year quarterly average of 88.8

Efficiency

How efficient is Corbus Pharmaceuticals Holdings business performance
CRBP's return on invested capital has surged by 97% since the previous quarter
The ROE rose by 40% QoQ and by 36% YoY
The ROA has increased by 27% from the previous quarter and by 20% YoY
Corbus Pharmaceuticals Holdings's return on sales has decreased by 21% QoQ

Dividends

What is CRBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRBP.

Financial health

How did Corbus Pharmaceuticals Holdings financials performed over time
Corbus Pharmaceuticals Holdings's total assets is 188% higher than its total liabilities
Corbus Pharmaceuticals Holdings's total assets has surged by 115% YoY and by 37% QoQ
The quick ratio has soared by 96% QoQ
CRBP's debt is 71% smaller than its equity
CRBP's debt has soared by 193% year-on-year
The company's equity has surged by 102% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.